Fast-growing small-caps: 2020s' ten-baggers from the Nordics and beyond

Which are the growth stars of the 2020s among small-cap companies?

I was listening to an episode of YLE’s Pörssipäivä (June 8, 2023) about small-caps. The guests were portfolio managers Jan Brännback and Janne Lähdesmäki from the asset management firm Schroders.

They mentioned that over the last 10 years, 70 Nordic listed companies have grown by 1000% or more. That is about 10% of the companies listed (10 years ago), which is quite a significant portion.

Now, of course, the dream would be to succeed in finding a few future ten-baggers oneself. As is likely the case for many others.

It would be nice to discuss these. Here are a few questions to consider:

-From which industries would it be wisest to search for companies now? And from which not?
-By what criteria can future ten-baggers best be identified?
-Which financial ratios are particularly worth examining?
-What good literature or other information have you read on this topic?
-In your opinion, what is the most essential question related to this?

In that radio program, they mentioned at least the company’s uniqueness, scalability, export orientation or export opportunities; apparently, it’s good to have some intangible and patentable expertise. Regarding sectors, they mentioned at least Health Tech, the IT sector, and even engineering firms.

53 Likes

This was a nice opening, as I have also been thinking about these things for over three decades myself. There is unlikely to be any so-called definitive answer, but there will probably be enough opinions and speculation to last a lifetime. At the very least, you need good innovations, solid management, often investors who believe in the cause, the ability to deliver the product or service to the customer, and a solution or benefit for the customer that they feel is worth their money and are even willing to commit to for the long term. Of course, moats and scalability are advantages for rapid growth. So-called good luck doesn’t hurt either, and you can give luck a better chance through hard work. It’s also good to remember this old saying: if you’re right but too early, you’re wrong. The market isn’t always ripe for even a great idea or product. These are fairly obvious points I’ve listed, so I won’t ramble on any further.

I can’t recommend any specific literature, but if I recall correctly, Verneri did a good summary (a video clip) on these multibaggers about a year ago? Maybe some forum member remembers better if it was him or someone else?

I have a highly diversified portfolio, in which I have also acquired a few companies that fit right into this thread. I could actually mention a couple:

Bioretec: first in the world to receive FDA approval for a biodegradable bone implant
Aiforia: AI-based tissue sample analysis. Strong partners

These are rewarding targets in the sense that both have Inderes coverage and good reports, from which you can then draw your own conclusions.

On the energy side, I strongly believe in the hydrogen sector, where green hydrogen production will grow very rapidly in the coming years. My portfolio includes Plug Power and Bloom Energy, among others. Similarly, solar power systems are becoming common globally at a fast pace. I have Enphase in my portfolio for that. The green transition also involves the domestic Spinnova, which has a killer concept at least on paper, as long as they can scale production fast enough and find enough demand for their fiber at a suitable price.

Of the above-mentioned, Enphase is already a stable and highly valued company, but I wouldn’t consider it 100% impossible for it to tenfold as well, if/when they add, for example, a compact home electrolyzer to their offering. A lot can happen in 10 years…

It could also be noted that a 10-bagger in business and a 10-bagger in value don’t always go hand in hand, but the price tag will certainly rise nicely if revenue increases tenfold without massive dilution of the share count. From an investment perspective, you still have to evaluate what a sensible purchase price is. P/S can be almost anything—let’s say between 0.2 and 50—and it is influenced by countless things, not least the prevailing hype around the topic.

Furthermore, as you asked about the most essential thing, it might be long-termism. The act of actually making a 10-bagger possible in your portfolio. The thing is, when a stock has multiplied several times over, there can be an irresistible urge to take profits or “swing trade” to buy back cheaper (which then never becomes possible and you miss the train). I have lost massive returns this way myself.
Another essential thing for me is that the company has ambitious goals, profit prospects, and the most credible roadmap possible, which is then consistently followed. (Well, it can be modified if there are good reasons as the world changes.)

These are not buy recommendations and I take the whole topic with a grain of salt, because predicting the future is quite difficult—since we can’t even always agree on the past : )

34 Likes

If I recall correctly, Bittium was mentioned there as well? So far, it has been an eternal promise, and big orders/profits are always coming next year.

3 Likes

I have invested in Swedish medtech companies, hoping, of course, to hit those tenbaggers. I’ve paid some “tuition fees” along the way as well, but at the moment, things are looking quite good again.

In Sweden, the small-cap lists (Spotlight and First North) are full of medtech and pharma companies built around some new innovation.

A few things I’ve learned along the way:

  • You have plenty of time and it’s worth boarding the train only at a fairly late stage, actually only once the product has already been authorized (EU and/or USA), sales have started, and positive cash flow is realistically in sight;

  • A rights issue typically causes the share price to crash, even by more than 50%, because the offering must be priced attractively and the price usually drops very close to the subscription price, only to recover slightly once the offering has been completed;

  • The ideal entry point is actually in connection with the last (easy to say…) rights issue; this emphasizes that cash flow must be about to turn positive;

  • So, by no means get involved with companies in the research phase (unless you want to, for example, support the development of treatments for some disease for selfless reasons);

  • If you invest in Sweden, it’s worth following Swedish discussion forums, such as Avanza and company-specific discussions on Discord / Facebook;

  • Of course, you have to keep your hype filter on at all times while reading the forums, but they contain a lot of useful information, data mining, and reflection, as long as you learn to distinguish the experts from the “experts.”

Personally, I am currently invested in companies called Braincool AB and Prostalund AB (not investment advice).

19 Likes

They mentioned that over the last 10 years, 70 listed Nordic companies have grown 1000% or more.

So if the stock price rises by only 2.2% per month, then in ten years it will be a 10-bagger.

edit:
I came across this on Twitter and thought it would fit this discussion:

11 Likes

I’ll throw out a couple of tips from the US market.

Endra: FDA De Novo approval in process for detecting fatty liver using ultrasound. They had cash in the bank when I last checked, and some kind of partnership—I believe it was with GE—is ready if approval is granted.

Profound Medical: A breakthrough is just around the corner, as it always is with these companies. TULSA treatment for prostate cancer. This type of device can be found in Finland as well, and an acquaintance of mine had their cancer treated with it. A doctoral thesis has even been written about this in Finland. FDA approval is expected in Q1/24, if I recall correctly.

9 Likes

Speaking from personal experience, at some point, my portfolio has included companies such as:

Revenio
Incap
Yleiselektroniikka (now Boreo)

Each of these went at least 10x after my purchase. However, I only managed to hold onto one, Revenio, to actually capture that >10x gain myself. If I had held the others for a bit longer, I would have gotten 10x from them as well.

Anyway… I ended up with these companies when I was looking for firms with the following characteristics:

  1. Small market cap, which usually leads to little market coverage, making it easier to find mispricings
  2. High ROE
  3. Profitable earnings
  4. Low valuation, e.g., P/E max 10

Based on my gut feeling, a multibagger consists of, for example:

A company with a P/E of 10 manages to significantly grow its earnings by, say, 100% through an acquisition, changing markets, or otherwise. The market starts pricing the company at higher valuation multiples, such as P/E 25–30. In this case, the stock should rise 500–600% to meet the market’s demand. So, the earnings don’t need to grow 10x; rather, the product of valuation multiples and earnings growth results in a steep rise in market price.

In the worst-case scenario, you’re left with a very profitable company in your portfolio. :man_shrugging:.

Maybe I could put LapWall in this category. The construction market is poor right now, but that cycle will turn eventually. I guess it doesn’t matter if you have to wait a couple of years if it gets you 10x :slight_smile:

29 Likes

In my opinion, characteristics of a multibagger also include:

  • Capable management
  • Massive market
  • Disruptive business model

These characteristics can be found by taking a look at the Hims & Hers Health thread (NYSE:HIMS).

6 Likes

Important factors:

  • High ROI/ROE
  • Low multiples
  • Opportunities to grow in target markets and growing markets
  • Low capital intensity
  • ”Boring”, but stable business

For example, I see Viafin Service as an excellent candidate

ROE/ROI ~20%
EV/EBIT ~7
Revenue €80M and target market size ~€2,000M, target market growing at about 4% per year
Low capital intensity and excellent investment opportunities
Cash is over a third of the market cap and the equity ratio is at a reasonable level, meaning the focus can be on the business instead of debt repayment.

12 Likes

Interesting topic. The big challenge, in my opinion, is finding those companies and also holding them long enough for the stock price to 10x.

Just screening through Swedish companies takes time, and you almost have to go through them one by one just to get some kind of general overview.

In my view, it is logical to start with the Small Cap list and/or the First North list.

Sweden is indeed a true treasure trove in the search for these ten-baggers. On top of that, valuation levels have recently melted down nicely, while at the same time, the companies are growing and developing. Unfortunately, here in Finland, we have largely missed out on this vibrant market. I have personally invested in, among others, BONESUPPORT and Surgical Science. Unfortunately, in both cases, at a fairly late stage.

7 Likes

Yes, Bittium was mentioned. In addition, Lumenradio and Össur were mentioned, and maybe SmartOptics as well. I’m starting to get interested in Össur, as they seem to be a pretty strong player in their field in those various limb supports and assistive devices. Osteoarthritis, sports injuries, and war injuries are growing that market.

Now that many sectors in Europe are stalling, everything even remotely related to defense technology is going quite strong. There could be some small firms with significant growth potential among the suppliers used by various weapon, missile, fighter jet, and helicopter manufacturers. Tracking down the most promising of these is not necessarily always easy, as not all information is public.

On the other hand, perhaps some not-so-obvious manufacturer of high-tech products related to the needs of defense forces and crisis preparedness. Manufacturers of supplies related to navigation, first aid, planning, transport, or other such areas.

1 Like

I’ve had this in my portfolio a few times from Stockholm’s First North.

Market cap well under 100 million (€), revenue has grown well, and operating profit and margins are in good shape.

The last quarterly report was just a disappointment – orders received fell and cash flow turned negative again.

4 Likes

Admittedly, there are several interesting companies on the Swedish side that could have multi-bagger potential. I personally hold BHG Group, which has been in trouble since the COVID boom as demand slumped significantly due to inflation and interest rates, leading to increased inventory levels. However, the business has now started taking steps toward pre-pandemic levels, and if I recall correctly, inventory has been reduced by 900m SEK, generating strong cash flow, which in turn has significantly lowered debt levels. It’s worth checking out; BHG has many other factors that make it an interesting company operating at the forefront of a megatrend.

Another one in my portfolio is Careium. It has shown good growth for several years/quarters but previously struggled with profitability. Now, this too has taken several steps for the better, which is reflected in the share price. It’s been about 6 months since my purchase, and the return so far is about 70%. Hopefully, it continues; I’m not planning to trim my position. The valuation is still very reasonable relative to growth. They are operating within what I consider perhaps the most significant megatrend: the aging of the population.

As an additional note, at the time of writing, BHG’s market cap is 2.27 billion SEK following yesterday’s 20% rise after the Q4 report. Careium’s market cap is 630 million SEK. So, we’re looking at very modest numbers.

8 Likes

My stock portfolio consists of only 3 companies in total, and I believe all of them have the potential to “ten-bag”: Optomed, Bioretec, and Faron :crossed_fingers:t2::folded_hands:t2:
All of these also have the possibility of being bought out before that, but that’s fine too at the right price :money_with_wings:

6 Likes

These are the companies mentioned in this thread so far. Some have even been given longer rationales. Thank you for those!

Bittium
Bioretec
Aiforia
Plug Power
Bloom Energy
Enphase
Spinnova
Braincool AB
Prostalund AB
Endra
Profound Medical
Revenio
Incap
Boreo
Lapwall
Hims & Hers
Viafin Service
Bonesupport AB
Surgical Science
Lumenradio
Össur
Smartoptics
W5 Solutions AB
BHG Group
Careium
Optomed
Faron

Quite a few medical companies on that list, although there are companies from other sectors as well. In any case, it’s an interesting list to look through and consider whether there is growth potential, if the timing is favorable for their products, and if the stock is at buy prices right now.

6 Likes

Here is a fast-growing and profitable one. :rocket:
https://keskustelut.inderes.fi/t/dlocal-limited-uruguayn-ensimmainen-yksisarvinen/37081

Over the last few months, several “bagger”/growth stock threads have appeared on the forum. Could these be bundled together more sensibly so that the discussion doesn’t get fragmented across multiple threads?
Ping @Verneri_Pulkkinen

3 Likes

Here is some reflection from Heikkilä & Vilén on the subject from about 3.5 years ago:

So, we were given 10 candidates, of which a surprisingly large percentage has left or is leaving the stock exchange. The time target for these was 5 years, which is quite tight. With 1.5 years left, it looks quite challenging.

It would be very interesting to get an update on the situation from the same gentlemen now that we have likely just passed the bottom for the Helsinki Stock Exchange (Hesuli) and are moving towards lower interest rates and hopefully towards brighter times in general.

3 Likes